Edgemond James, who serves as Chief Financial Officer and Treasurer of United Therapeutics (NASDAQ: UTHR), sold 8,494 shares of the company’s common stock on April 9, 2026. The block of shares was sold across several transactions, with per-share prices ranging from $574.868 to $582.3023, producing total gross proceeds of approximately $5.77 million.
On the same trading day, James exercised stock options covering 10,000 shares at an exercise price of $135.42, an exercise that required $1,354,199 in total. Following the combination of the sales and the option exercise, James directly owns 18,876 shares of United Therapeutics.
The timing of the sales coincided with United Therapeutics shares trading near a 52-week peak of $607.89, after the stock had appreciated roughly 105% over the prior 12 months. United Therapeutics is currently valued at $25.03 billion. According to InvestingPro analysis cited with the company’s valuation data, United Therapeutics appears overvalued on the platform’s metrics; InvestingPro also notes 14 additional InvestingPro Tips and detailed valuation metrics on its Most Overvalued stocks listing.
Investor focus on United Therapeutics has intensified for a number of reasons beyond insider activity. Raymond James initiated coverage with an Outperform rating and set a $700 price target, pointing to the potential for Tyvaso to achieve more than $5 billion in peak sales in idiopathic pulmonary fibrosis. Additional analyst moves followed recent clinical developments related to Tyvaso and trial results.
H.C. Wainwright raised its price target to $660, citing strong data from the TETON-1 trial for Tyvaso and the implications for expansion into idiopathic pulmonary fibrosis. BofA Securities increased its target to $626 while maintaining a Neutral rating, referencing positive Phase 3 trial results for Tyvaso. Jefferies boosted its target to $733, stating that the successful TETON-1 study improved the probability of success for the pulmonary fibrosis indications.
Regulatory progress has also drawn attention. The U.S. Food and Drug Administration granted Regenerative Medicine Advanced Therapy, or RMAT, designation to miroliverELAP, an investigational liver assist device developed by Miromatrix Medical Inc., a subsidiary of United Therapeutics. The RMAT designation is noted in coverage as an indicator of regulatory recognition for the device’s potential.
Summary
United Therapeutics’ CFO sold 8,494 shares on April 9, 2026, realizing $5.77 million at prices between $574.868 and $582.3023, and exercised 10,000 options at $135.42 on the same day. Post-transactions, his direct holdings total 18,876 shares. The trades occurred while the stock traded close to its 52-week high of $607.89 after a 105% annual gain. The company is valued at $25.03 billion and appears overvalued per InvestingPro; multiple analysts have raised price targets amid strong Tyvaso trial data and an RMAT designation for a subsidiary device.
Key points
- Insider activity: CFO Edgemond James sold 8,494 shares for $5.77 million and exercised 10,000 options at $135.42 on April 9, 2026.
- Market context: Sales occurred as UTHR traded near its 52-week high of $607.89 after a 105% gain over the past year; company valuation is $25.03 billion.
- Analyst and regulatory developments: Several firms raised price targets for United Therapeutics following positive Tyvaso trial data, and the FDA granted RMAT designation to miroliverELAP from subsidiary Miromatrix Medical Inc.
Risks and uncertainties
- Valuation risk: InvestingPro’s analysis lists United Therapeutics as appearing overvalued, which could influence market sentiment and investor decisions - impacting equity markets and healthcare sector valuations.
- Clinical and regulatory execution: Continued reliance on Tyvaso’s trial outcomes and the regulatory path for subsidiary devices creates uncertainty for the company’s anticipated revenue trajectory - relevant to pharmaceutical and medical device sectors.
- Insider selling perception: The CFO’s sale, timed while shares traded near their yearly high, may be viewed by some investors as a liquidity event and could affect short-term stock dynamics - a market liquidity and investor sentiment risk.